Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

140.67 +0.73 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments. 
Via Benzinga
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Biogen Inc.
Via GlobeNewswire
Biogen Analysts Lower Their Forecasts After Q4 Results
 
Via Benzinga
Forecasting The Future: 10 Analyst Projections For Biogen
 
Via Benzinga
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers. 
Via Benzinga
Top S&P500 movers in Wednesday's session
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook
Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop. 
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below. 
Via Chartmill
These S&P500 stocks are moving in today's session
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Earnings Scheduled For February 12, 2025
 
Via Benzinga
Breaking Down Biogen: 18 Analysts Share Their Views
 
Via Benzinga
Biogen (BIIB) Q4 2024 Earnings Call Transcript
BIIB earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New... 
Via Benzinga
Topics Economy
Wednesday's session: gap up and gap down stock in the S&P500 index
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip
The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected. 
Via Stocktwits
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma. 
Via Benzinga
Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3%... 
Via StockStory
Topics Artificial Intelligence
Why Investors Might Hammer Biogen Despite Its Earnings Beat
Biogen beat Q4 views Wednesday, but guided lower on 2025 profit. 
Via Investor's Business Daily
US Stocks Set For A Cautious Start Ahead Of Inflation Data: Expert Says 'Strong Bull Markets Tend To Roar Back To Life After Corrections'
U.S. stock futures fell on Wednesday after a mixed close on Tuesday as Federal Reserve Chairman Jerome Powell Congress testimony. 
Via Benzinga
Topics Economy
Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
 
Via Benzinga
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings. 
Via Benzinga
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok. 
Via Benzinga
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
From Biogen Inc.
Via GlobeNewswire
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders. 
Via Stocktwits
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA 
From Biogen Inc.
Via GlobeNewswire
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback